BMRN - BioMarin Pharmaceutical Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
95.70
+0.95 (+1.00%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close94.75
Open93.95
Bid0.00 x 1000
Ask0.00 x 900
Day's Range92.80 - 96.67
52 Week Range75.81 - 106.74
Volume640,563
Avg. Volume1,187,009
Market Cap17.041B
Beta (3Y Monthly)1.71
PE Ratio (TTM)N/A
EPS (TTM)-0.71
Earnings DateOct 24, 2018 - Oct 29, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est121.67
Trade prices are not sourced from all markets
  • Gauging Analysts’ Views on Clovis Stock
    Market Realist3 days ago

    Gauging Analysts’ Views on Clovis Stock

    In November, of the 12 analysts covering Clovis Oncology (CLVS) stock, seven have given it “buy” or higher ratings, and five have given it “hold” ratings.

  • A grandpa's hope for hemophilia cure leads him to gene therapy clinical trial
    CNBC3 days ago

    A grandpa's hope for hemophilia cure leads him to gene therapy clinical trial

    BioMarin's clinical trial of a gene therapy for hemophilia is providing hope to patients with the disease. It is an experimental treatment that uses a virus to deliver a healthy copy of a gene to make up for one that causes excessive bleeding.

  • Understanding Clovis Oncology’s Gross Margin Trend
    Market Realist4 days ago

    Understanding Clovis Oncology’s Gross Margin Trend

    For 2018 and 2019, Clovis Oncology (CLVS) is expected to generate revenues of $88.79 million and $165.13 million, respectively, compared to its revenue of $55.51 million in 2017.

  • Exploring Clovis Oncology’s Operational Performance
    Market Realist4 days ago

    Exploring Clovis Oncology’s Operational Performance

    Clovis Oncology (CLVS) incurred selling, general, and administrative expenses of $42.49 million in the third quarter compared to $35.01 million in the third quarter of 2017. This increase was due to higher commercialization activities for Rubraca and preparation for its expected launch in Europe.

  • MarketWatch5 days ago

    Sangamo stock drops after J.P. Morgan downgrade

    Sangamo Therapeutics Inc. shares dropped as much as 10% in Wednesday premarket trade before evening out to a 4.6% decline after the company was downgraded to "neutral" at J.P. Morgan, with analyst Eric Joseph citing "growing skepticism about the company's lead development programs and their potential for value creation over the foreseeable future." Joseph also cut the company's price target by nearly 70% to $11. (Company shares closed at $10.80 on Tuesday.) Sangamo is a buzzy biotechnology company that focuses on a type of cutting-edge gene editing that utilizes "zinc finger" proteins. But whether the company's SB-525 program for hemophilia A is working "continues to elude, now with indefinite timelines," Joseph said, questioning whether the company can beat further-along competitors like BioMarin Pharmaceutical Inc. and Spark Therapeutics Inc. . The analyst also had questions about the company's SB-913 program, being developed for a metabolic disorder called Hunter syndrome; early results from a trial were recently released to skepticism, causing Sangamo shares to plummet. "We do believe that the breadth of the pipeline offers several potential catalysts longer term (12-18 months), but with management credibility increasingly coming into play, net-net, we view SGMO as a show-me story from here," Joseph said. Sangamo shares have dropped 32.1% over the last three months, compared with a 3.5% decline in the S&P 500 .

  • Jazz Pharmaceuticals: A Financial Overview in November
    Market Realist6 days ago

    Jazz Pharmaceuticals: A Financial Overview in November

    Jazz Pharmaceuticals generated revenues of $469.4 million in the third quarter, which reflects ~14% YoY (year-over-year) growth. Jazz Pharmaceuticals’ net revenues over the first nine months of 2018 were $1.4 billion—compared to $1.2 billion in the same period in 2017, which reflects ~20% YoY growth.

  • BioMarin and Believe Limited Announce the Debut of 'Hemophilia: The Musical'
    PR Newswire7 days ago

    BioMarin and Believe Limited Announce the Debut of 'Hemophilia: The Musical'

    SAN RAFAEL, Calif., Nov. 12, 2018 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (BMRN) today announced the debut of the Broadway-style 'Hemophilia: The Musical,' a first-of-its-kind theatrical production featuring 25 students affected by a bleeding disorder. A recording of the six-song performance is now available at BreakingThroughHemophilia.com. "'Hemophilia: The Musical' was a defining moment for many of the young adults who participated," said Patrick James Lynch, Believe Limited CEO and Breaking Through! Musical Theater Intensive director.

  • See what the IHS Markit Score report has to say about Biomarin Pharmaceutical Inc.
    Markit10 days ago

    See what the IHS Markit Score report has to say about Biomarin Pharmaceutical Inc.

    Biomarin Pharmaceutical Inc NASDAQ/NGS:BMRN

  • PR Newswire11 days ago

    BioMarin to Participate in Two Investor Conferences in November

    - Credit Suisse 27th Annual Credit Suisse Healthcare Conference on November 13 in Scottsdale, AZ - Evercore ISI HealthConX Conference on November 28 in Boston SAN RAFAEL, Calif. , Nov. 8, 2018 /PRNewswire/ ...

  • Investopedia11 days ago

    10 Health Care Stocks Seen Jumping on Takeovers

    Mergers and acquisitions have been proceeding at a torrid pace, and the health care sector may be an especially active area for future consolidation. In the first half of 2018, the value of M&A deals hit all-time records both worldwide and in the U.S., up by 64% and 79%, respectively, from the first half of 2017, per data from Thomson Reuters cited by Axios.com. Per Business Insider, these are the top 10 takeover candidates that Morgan Stanley sees in the health care sector: IQVIA Holdings Inc. ( IQV), BioMarin Pharmaceutical Inc. ( BMRN), Seattle Genetics Inc. ( SGEN), DaVita Inc. ( DVA), Universal Health Services Inc. ( UHS), Dexcom Inc. ( DXCM), Neurocrine Biosciences Inc. ( NBIX), Perrigo Co. PLC ( PRGO), Nektar Therapeutics ( NKTR), and Sarepta Therapeutics  Inc. ( SRPT).

  • PR Newswire12 days ago

    BioMarin Highlights Breadth of Innovative Development Pipeline at R&D Day on November 7th in New York

    SAN RAFAEL, Calif., Nov. 7, 2018 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (BMRN) updated the investment community on the Company's research and development portfolio, which is focused on innovative therapies to treat rare and ultra-rare diseases. BioMarin announced today that the Phase 3 study of vosoritide in children is now fully enrolled and top line results are planned for the end of 2019.  BioMarin has also initiated a global Phase 2 study in infants and young children up to age 5 with achondroplasia.  See "About Vosoritide Phase 3 Study" below for more information on this study.

  • See what the IHS Markit Score report has to say about Biomarin Pharmaceutical Inc.
    Markit17 days ago

    See what the IHS Markit Score report has to say about Biomarin Pharmaceutical Inc.

    Biomarin Pharmaceutical Inc NASDAQ/NGS:BMRN

  • PR Newswire18 days ago

    BioMarin to Highlight Breadth of Innovative Development Pipeline at R&D Day on November 7th in New York

    Key Research & Development Pipeline Products and Data to be Presented, Including: - Vosoritide for the Treatment of Achondroplasia 42-Month Data Update - Gene Therapy Product for the Treatment of Phenylketonuria ...

  • BioMarin Keeps on Pace for Its $2 Billion Goal
    Motley Fool19 days ago

    BioMarin Keeps on Pace for Its $2 Billion Goal

    The orphan-disease drugmaker continues to register revenue growth.

  • Why Incyte’s Q3 2018 Earnings Beat Revenue Estimates
    Market Realist20 days ago

    Why Incyte’s Q3 2018 Earnings Beat Revenue Estimates

    Incyte (INCY) released its Q3 2018 earnings today. The company beat Wall Street analysts’ estimates for revenue but missed estimates for EPS. It reported EPS of $0.14 on revenues of $449.68 million in the third quarter of 2018, compared to estimates for EPS of $0.40 on revenues of $449.20 million.

  • Allergan Beats EPS and Revenue Estimates: Q3 2018 Earnings
    Market Realist20 days ago

    Allergan Beats EPS and Revenue Estimates: Q3 2018 Earnings

    Allergan (AGN) released its Q3 2018 earnings today. The company beat Wall Street analysts’ estimates for EPS and revenues, and it reported non-GAAP EPS of $4.25 on revenues of $3.91 billion, compared to estimates for EPS of $4.03 on revenues of $3.88 billion during the third quarter of 2018.

  • GlobeNewswire20 days ago

    Research Report Identifies Deckers Outdoor, Navient, Phillips 66, BioMarin Pharmaceutical, McKesson, and Equity Residential with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement

    NEW YORK, Oct. 30, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • Shire’s Q3 2018 Earnings: Analyst Estimates
    Market Realist20 days ago

    Shire’s Q3 2018 Earnings: Analyst Estimates

    Shire (SHPG) is a biotechnology company focused on discovering, developing, and commercializing specialty medicines to treat rare diseases and other specialized conditions. Shire is set to release its third quarter of 2018 earnings on November 1. Wall Street analysts estimate EPS of $3.58 on revenues of $3.82 billion.

  • Thomson Reuters StreetEvents23 days ago

    Edited Transcript of BMRN earnings conference call or presentation 25-Oct-18 8:30pm GMT

    Q3 2018 Biomarin Pharmaceutical Inc Earnings Call

  • BioMarin (BMRN) Q3 Earnings & Revenues Surpass Estimates
    Zacks24 days ago

    BioMarin (BMRN) Q3 Earnings & Revenues Surpass Estimates

    BioMarin's (BMRN) Q3 scores on earnings and revenue beat with a surge in demand for its key products.

  • What Analysts Recommend for Incyte ahead of Q3 Earnings
    Market Realist24 days ago

    What Analysts Recommend for Incyte ahead of Q3 Earnings

    Wall Street analysts estimate Incyte’s (INCY) revenues will increase by ~17.7% to $449.2 million during the third quarter of 2018 compared to revenues of $381.5 million during the third quarter of 2017. Also, the earnings per share are estimated to be $0.40 for the third quarter of 2018 as compared to earnings per share of $0.08 for the third quarter of 2017. Incyte stock has fallen nearly 46.6% over the last 12 months and decreased by ~35.7% in 2018 year-to-date.

  • Benzinga24 days ago

    The Daily Biotech Pulse: Gilead's Q2, Syndax Breast Cancer Drug Setback, Synergy Pharma On Brink Of Default

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Oct. 26) Endocyte, Inc. (NASDAQ: ECYT ) Imprimis Pharmaceuticals ...

  • How Sarepta Therapeutics Fared in the Third Quarter
    Market Realist24 days ago

    How Sarepta Therapeutics Fared in the Third Quarter

    Sarepta Therapeutics (SRPT) released its third-quarter 2018 results on October 24. Its net loss per share was $1.15 in the third quarter of 2018 as compared with net loss per share of $0.78 in the third quarter of 2017.

  • Biomarin Pharmaceutical Inc (BMRN) Q3 2018 Earnings Conference Call Transcript
    Motley Fool24 days ago

    Biomarin Pharmaceutical Inc (BMRN) Q3 2018 Earnings Conference Call Transcript

    BMRN earnings call for the period ending September 30, 2018.

  • Associated Press24 days ago

    BioMarin: 3Q Earnings Snapshot

    On a per-share basis, the San Rafael, California-based company said it had a loss of 7 cents. Earnings, adjusted for stock option expense, came to 14 cents per share. The results topped Wall Street expectations. ...